Z. Younossi

Publications1,224
h-index108
Citations64,863
Highly Influential Citations2,496
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Stepanova
  • 413 Publications • 10,809 Citations
  • L. Henry
  • 272 Publications • 13,950 Citations
  • A. Sanyal
  • 1,117 Publications • 78,705 Citations
  • R. Loomba
  • 899 Publications • 32,658 Citations
  • Publications
  • Influence
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
TLDR
As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Abstract This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A "Guidance" document is different from a "Guideline." Guidelines are…
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the…
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the…
The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the…
TLDR
This is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently.
Sofosbuvir for previously untreated chronic hepatitis C infection.
TLDR
In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and…
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and…
Telaprevir for retreatment of HCV infection.
TLDR
Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase.
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
TLDR
The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy.
Nonalcoholic steatohepatitis
TLDR
Initial treatment protocols for NASH focus on various aspects of injury in an attempt to control insulin imbalances, improve lipid regulation, reduce free radicals, and ameliorate the inflammatory process.
...
1
2
3
4
5
...